Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in the courts. Earlier this month ...

GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrative – and likely ...

The FDA approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new ...

GSK shares are trading cheaply and offering potential passive income. So is this FTSE 100 stock a no-brainer buy for my ...

The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...

The approval was based on data from two late-stage trials showing the drug was superior to nitrofurantoin, the ...

REUTERS/Chris J. Ratcliffe/File Photo GSK is banking on new drugs in its infectious diseases portfolio, including its recently launched respiratory syncytial virus vaccine, to make up for lost ...

Blujepa, which treats UTIs in female patients aged 12 and up with common and uncomplicated infections, will hit the market in ...

Novavax reached a settlement with Gavi, the Vaccine Alliance, after t | International vaccine partnership Gavi has ...

The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...